Capecitabine-mediated heart failure in colorectal cancer: a case series

Erin N. McAndrew 1, Davinder S. Jassal 1,2,3,4, Benjamin A. Goldenberg 1,5, and Christina A. Kim1,5,6*

1Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada; 2Institute of Cardiovascular Sciences, St. Boniface Hospital, University of Manitoba, Winnipeg, Manitoba, Canada; 3Section of Cardiology, Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada; 4Department of Radiology, St. Boniface Hospital, University of Manitoba, Winnipeg, Manitoba, Canada; 5Section of Medical Oncology and Haematology, Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, 409 Tache Ave, Winnipeg, Manitoba R2H 2A6, Canada; and 6Research Institute in Oncology and Hematology, Cancer Care Manitoba, Winnipeg, Manitoba, Canada

Received 1 September 2020; first decision 28 October 2020; accepted 4 February 2021

Background

Capecitabine is a pyrimidine antimetabolite that inhibits thymidylate synthase and is commonly used in the treatment of colorectal cancer. Adverse cardiac side effects are reported in 1–18% of patients receiving Capecitabine. The most commonly proposed mechanism of cardiotoxicity in the setting of Capecitabine use is vasospasm of the coronary arteries. However, cardiotoxicity can also present as an acute coronary syndrome, arrhythmia, hypertension, and/or sudden cardiac death. Profound non-vasospastic cardiotoxicity is rare.

Case summary

We describe two cases of acute heart failure leading to cardiogenic shock in patients shortly after exposure to Capecitabine. Both patients did not demonstrate the characteristic transient ST elevation seen in patients with coronary artery vasospasms secondary to Capecitabine. Both patients required admission to the Acute Cardiac Care Unit requiring vasopressor and inotropic support. Thorough diagnostic investigations including echocardiography, cardiac magnetic resonance imaging, and cardiac computed tomography did not identify infarction, myocarditis, or any infiltrative process to explain their symptoms. Both patients had complete resolution of cardiac function, with no long-term sequelae.

Discussion

In patients receiving Capecitabine, reversible heart failure leading to cardiogenic shock should be considered as a potential cardiotoxic side effect.

Keywords

Heart failure • Cardiogenic shock • Capecitabine • Cardiotoxicity • Cardio-oncology • Case report

Learning points

• Cardiotoxicity is a rare side effect of capecitabine chemotherapy, most commonly secondary to coronary artery vasospasm.
• Acute heart failure leading to cardiogenic shock is a rare form of cardiotoxicity that should be considered in patients on capecitabine.

* Corresponding author. Tel: +1 204 237 2006, Email: ckim3@cancercare.mb.ca
Handling Editor: Hatem Soliman Aboumarie
Peer-reviewers: Domenico D’Amario and Sherif Mohammad Abd EI-Samad
Compliance Editor: Brett Sydney Bernstein
Supplementary Material Editor: Ayse Dijadit
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Introduction

Capecitabine is the oral pro-drug of 5-Fluorouracil (5-FU) and is a pyrimidine antimetabolite that inhibits thymidylate synthase. Fluoropyrimidine-based chemotherapy is a vital aspect of the treatment of colorectal cancer. Side effects of fluoropyrimidine therapy may include myelosuppression, mucositis, nausea, emesis, diarrhoea, palmar-plantar erythrodysesthesia, and rarely cardiotoxicity. Cardiotoxicity can present as an acute coronary syndrome, arrhythmia, hypotension, cardiogenic shock, cardiac arrest, and/or sudden cardiac death. The most commonly proposed mechanism of cardiotoxicity in the setting of Capecitabine is vasospasm of the coronary arteries. There is pre-clinical and clinical data that suggests that 5-FU causes vasospasm in a dose–dependent manner. Profound non-vasospastic cardiotoxicity is rare. We describe two cases of acute heart failure leading to cardiogenic shock in patients shortly after exposure to Capecitabine.

Timeline

| Time | Event |
|------|-------|
| Patient 1 | Day 1 | Started neoadjuvant chemotherapy with Capecitabine and Oxaliplatin (CAPOX). |
| | Day 2 | Admitted to Acute Cardiac Care Unit with cardiogenic shock requiring vasopressor and inotropic support with norepinephrine and milrinone. |
| | Day 3 | TTE revealed LVEF <20% with severely depressed right ventricular systolic function. |
| | Day 4 | Coronary angiography revealed no obstructive coronary artery disease. |
| | Day 5 | Patient weaned off norepinephrine and milrinone, transferred to Cardiology Ward. |
| | Day 6 | Cardiac magnetic resonance imaging (MRI) demonstrated LVEF of 32% with a hypokinetic left ventricle, with no evidence of myocarditis, infarction, or an infiltrative process. |
| | Day 7 | Discharged from hospital. |
| | Four months later | Repeat cardiac MRI showed significant improvement of LVEF to 59%. |

Case presentations

Patient 1

A 32-year-old woman, with no personal or family history of cardiac disease, underwent a diverting ostomy for an obstructing rectal cancer. Staging revealed a clinical T4N2M1 moderately differentiated adenocarcinoma. She was started on neoadjuvant chemotherapy with Capecitabine and Oxaliplatin (CAPOX; Oxaliplatin (130 mg/m²) on Day 1, and oral Capecitabine twice daily (1000 mg/m²) on Days 1–14 of a 3 weeks cycle]. On Day 7 of Cycle 1, she presented with nausea, vomiting, weakness, shortness of breath, and pleuritic chest discomfort.

In Urgent Care, she was afebrile with a blood pressure of 100/71 mmHg and a heart rate of 140–160 b.p.m. Her respiratory rate was 18 with an oxygen saturation of 100% on room air. She appeared unwell and pale but was alert and oriented. Cardiac examination revealed normal heart sounds, with no murmurs or extra heart sounds. Jugular venous pressure (JVP) was elevated and there was no peripheral oedema. An electrocardiogram (ECG) demonstrated sinus tachycardia with T-wave inversion laterally and non-specific ST changes (Figure 1A). A venous blood gas revealed a pH 7.44, pO2 32 mmHg, bicarbonate 25 mmol/L, pCO2 38 mmHg, and lactate 2.4 mmol/L. Once the patient was haemodynamically stable, she received diuresis for management of pulmonary oedema. Her tachycardia and dyspnoea did not improve despite diuresis, and her lactate continued to increase to 4.1 mmol/L. A transthoracic echocardiogram (TTE)
demonstrated a significantly reduced left ventricular ejection fraction (LVEF) of <20% on the apical four-chamber view following the administration of definity for left ventricular opacification (Figure 2A).

The patient was diagnosed with cardiogenic shock secondary to cardiomyopathy of unknown cause. She was admitted to the Acute Cardiac Care Unit for inotropic support with milrinone and haemodynamic monitoring. Infectious causes of myocarditis, including HIV, hepatitis, and parvovirus, and an autoimmune work-up were negative. Cardiac magnetic resonance (CMR) imaging on admission Day 5 showed an LVEF of 58%, LV end-diastolic volume of 104 mL, LV end-systolic volume of 43 mL, and LV stroke volume of 61 mL. Additionally, the RV volumes and RV systolic function were normal on CMR imaging. There was no evidence of delayed enhancement of the left ventricular myocardium on CMR imaging to suggest a recent infarction, myocarditis, or infiltrative process. Additionally, T1 myocardial mapping and T2 weight imaging on CMR showed no evidence of myocardial oedema.

During her admission, she had an elevated lactate for ~2 weeks and required inotropic support with milrinone for a total of 16 days. A repeat transthoracic echocardiography 14 days post-admission

Figure 1 (A) Patient 1: a 12-lead electrocardiogram demonstrating sinus tachycardia with non-specific ST changes. (B) Patient 2: a 12-lead electrocardiogram demonstrating sinus tachycardia.
demonstrated normal cardiac function, and she has successfully weaned off milrinone and discharged home on Metoprolol and Ramipril. Two months after discharge, a cardiac computed tomography scan demonstrated no evidence of obstructive coronary artery disease. She was started on Raltitrexed and Oxaliplatin for ongoing management of the rectal cancer and has experienced no further cardiotoxicity.

**Patient 2**

A 58-year-old functionally well man with a past medical history of hypertension, gout, and alcohol use (3–4 drinks per day), and no personal or family history of cardiac disease, presented post-operatively with a T4aN1aM0 moderately differentiated adenocarcinoma of the upper rectum. Eight weeks after low anterior resection, he received a recommendation of adjuvant CAPOX chemotherapy with chemoradiation. On Day 2 of Cycle 1, he experienced two 30-min episodes of central chest pain while at rest, associated with diaphoresis. On Day 3, his chest pain increased in severity and was associated with profound fatigue, leading him to seek medical attention.

In the emergency department, he was afebrile with a blood pressure of 91/69 mmHg, heart rate of 109 b.p.m., and oxygen saturation of 100% on room air. A cardiovascular exam revealed normal heart sounds, with no murmurs or extra heart sounds. His JVP was elevated to angle of jaw, and he had mild pitting oedema to his ankles. An ECG demonstrated sinus tachycardia and no evidence of ischaemia (Figure 1B). A chest X-ray revealed pulmonary oedema. His serial hsTnT measurements were 233 and 226.

A venous blood gas revealed a pH 7.38, pCO₂ 38 mmHg, bicarbonate 21 mmol/L, and lactate 3 mmol/L. Point of care ultrasound demonstrated a hypokinetic left ventricle, a grossly reduced LVEF, and a dilated IVC with minimal inspiratory response. He remained hypotensive with systolic blood pressures of 80 mmHg despite resuscitation with 4 L of normal saline. He developed clinical signs of heart failure, including increasing oxygen requirements and shortness of breath. He was admitted to the Acute Cardiac Care Unit for

![Figure 2](https://academic.oup.com/ehjcr/article-fig/5/3/ytab079/6156327)

(A) Patient 1: an apical four-chamber view on transthoracic echocardiography with definity for left ventricular opacification demonstrating severe left ventricular systolic dysfunction with an left ventricular ejection fraction <20%. (B) Patient 1: a horizontal long-axis view on balanced steady-state free precession images demonstrating an improvement in left ventricular systolic function on inotropic support. (C) Patient 2: an apical four-chamber view on transthoracic echocardiography confirming severe left ventricular systolic dysfunction with a left ventricular ejection fraction <20%. (D) Patient 2: a horizontal long-axis view on balanced steady-state free precession images demonstrating an improvement in left ventricular ejection fraction to 32% 5 days after the initial transthoracic echocardiography.
Capecitabine-mediated heart failure in colorectal cancer

Capecitabine is a pro-drug that is catalysed by thymidine phosphorylase to fluorouracil. Thymidine phosphorylase has high expression in cancer cells, allowing for more selective accumulation of the anti-metabolite in the tumour. Although Capecitabine is more selective to tumour cells, the reported incidence of cardiotoxicity with Capecitabine is similar to 5-FU, occurring in 1–18% of patients.

Cardiotoxicity can present with a range of symptoms including angina, arrhythmias, cardiogenic shock, and even sudden cardiac death. Classically, patients with coronary vasospasm present similar to other causes of acute coronary syndromes, with angina, but transient ST deviation on ECG. Coronary angiography with provocative testing can support the diagnosis of coronary vasospasm by direct visualization demonstrating no thrombus or narrowing. However, this direct visualization of vasospasm is time sensitive, due to the dose–dependent relationship of vasospasm and fluoropyrimidine cardiotoxicity. Both of the cases described herein showed no evidence of regional wall motion abnormalities or obstructive coronary artery disease on cardiac imaging. Although coronary vasospasm can lead to development of cardiogenic shock, other mechanisms, such as toxic myocardial inflammation or stress myocardopathy, resulting in myocardial dysfunction may better explain the mechanism of cardiogenic shock in these two cases.

In both cases, non-invasive diagnostic images, including TTE and CMR, were used to confirm the presence of severe left ventricular systolic dysfunction. One limitation of our case series is the lack of myocardial biopsy, which may have provided additional information on the mechanism of cardiotoxicity. However, since there was no evidence of delayed enhancement of the left ventricular myocardium on CMR to suggest myocarditis, or an infiltrative or ischaemic process, we elected not to pursue an invasive myocardial biopsy.

Both of our patients received CAPOX chemotherapy and presented with cardiogenic shock within days of starting chemotherapy. This timeline is similar to what has been reported in a retrospective study, which demonstrated that the first occurrence of cardiotoxicity occurred within 3–6 days of starting chemotherapy. In a prospective study of patients receiving 5-FU and oxaliplatin, 8.5% of patients experienced clinical symptoms of cardiotoxicity, which was associated with biochemical changes including an elevated N-terminal pro-brain natriuretic peptide and lactic acid, but not necessarily a change in global LVEF. Moreover, the same study found that plasma lactic acid increases significantly during 5-FU treatment, regardless of whether the patient had symptomatic cardiotoxicity. This could potentially explain the 2 weeks of elevated serum levels of lactate in Patient 1. It is also possible that the elevated lactate, in this case, was due to the continued stress on the myocardium from severe cardiac dysfunction caused by Capecitabine.

Some of the risk factors for developing cardiotoxicity to fluoropyrimidines include pre-existing cardiovascular disease, continuous infusion schedules, and concomitant cisplatin treatment. Although pre-existing cardiovascular disease has been shown to significantly predispose patients to fluorouracil-associated cardiotoxicity, with a relative risk of 6.83, a systematic review showed conflicting results.

Of interest, the patient in Case 2 had predisposing cardiovascular risk factors (hypertension and alcohol use), potentially increasing his risk of cardiotoxicity from Capecitabine, despite exhibiting no exercise-limiting symptoms at baseline. For high-risk patients that require additional chemotherapy treatment, changing the agent to one with a safer cardiac profile should be considered. For example, the patient in case 1 received Raltitrexed, a quinazoline antifolate that selectively inhibits thymidylate synthase and has been shown to have outcomes similar to 5-FU in the treatment of metastatic colorectal cancer. Raltitrexed appears to have a safer cardiac profile for high-risk patients who have experienced cardiotoxicity on 5-FU based regimens.

Dihydropyridine dehydrogenase (DPD) is the enzyme involved in the rate-limiting catabolism of 5-FU. Dihydropyridine dehydrogenase deficiency predisposes individuals to severe 5-FU toxicity, including profound neutopenia, mucositis, diarrhoea, and vomiting. In patients with DPD-deficiency, the onset of 5-FU toxicity can be rapid, sometimes even within hours of the first dose. In such cases, an antidote, uridine triacetate, can be considered. The patients in our case series did not present with these classic symptoms of DPD-deficiency and, therefore, DPD testing was not pursued.

Although both patients described here did not have long-term cardiac dysfunction, some patients may experience irreversible cardiac damage. When patients experience cardiotoxicity related to an anticancer agent, referral to a cardio-oncology specialist is recommended, as such an approach may result in improved cardiac optimization, higher rates of cancer treatment continuation, and ultimately improved oncologic outcomes. Additionally, for patients who have cardiac risk factors, referral to a cardio-oncology specialist pre-chemotherapy can allow for cardiac optimization and ultimately improve completion of cancer therapy.
Conclusion

In patients receiving Capecitabine, reversible heart failure and cardiogenic shock should be considered as a potential cardiotoxic side effects. Capecitabine should be promptly discontinued and patients should be managed with multidisciplinary collaboration from the disciplines of Cardiology and Oncology.

Lead author biography

Dr Erin McAndrew is an Internal Medicine resident at the University of Manitoba. She completed a Master of Science and Doctor of Medicine at the University of Manitoba. Her research interests include cardio-oncology and long-term cardiac consequence of chemotherapy.

Supplementary material

Supplementary material is available at European Heart Journal - Case Reports online.

Slide sets: A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data.

Consent: The authors confirm that written consents for submission and publication of this case report including images and associated text have been obtained from the patients in line with COPE guidance.

Conflict of interest: C.A. Kim reports a research grant from Celgene, outside of this submitted work. No other conflicts of interest are declared.

Funding: None declared.

References

1. Miwa M, Ura M, Niishida M, Sawada N, Ishikawa T, Mori K et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5 fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274–1281.

2. Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev 2013;39:974–984.

3. Layoun ME, Wickramasinghe CD, Peralta MV, Yang EH. Fluoropyrimidine-induced cardiotoxicity: manifestations, mechanisms, and management. Curr Oncol Rep 2016;18:1–12.

4. Mosseri M, Fingert HJ, Varticovski L, Chokshi S, Inner JM. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res 1993;53:3028–3033.

5. Sudhoff T, Enderle MD, Pahlke M, Petz C, Teschendorf C, Graeven U et al. Fluorouracil induces arterial vasoconstrictions. Ann Oncol 2004;15:661–664.

6. Van Cutsem E, Hoff PM, Blum JL, Abt M, Osterwalder B. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 2002;13:484–485.

7. Becker K, Eckenbrecht BT, Haussinger D, Frielingsdorf T. Cardiotoxicity of the anti-proliferative compound fluorouracil. Drugs 1999;57:475–484.

8. Jensen SA, Hasbak P, Mortensen J, Sørensen JB. Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. J Clin Oncol 2010;28:5280–5286.

9. Eskandari MR, Moghadam F, Shahraki J, Pourahmad J. A comparison of cardiomyocyte cytotoxic mechanisms for 5-fluorouracil and its pro-drug capecitabine. Xenobiotica 2015;45:79–87.

10. Raber I, Warack S, Kanduri J, Pribish A, Godishala A, Abovich A et al. Fluoropyrimidine-associated cardiotoxicity: a retrospective case-control study. Oncologist 2020;25:606–609.

11. Meyer CC, Calis KA, Burke LB, Walawander CA, Grasela TH. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 1997;17:729–736.

12. Maughan TS, James RD, Kerr DJ, Ledermann JA, Mcardle C, Seymour MT et al. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002;359:1555–1563.

13. Kelly C, Bhua N, Harrison M, Buckley A, Saunders M. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history. Eur J Cancer 2013;49:2303–2310.

14. Kuilenburg ABPV, Haasjes J, Richel DJ, Zoetekouw L, Lenthe H, Van D, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene. Clin Cancer Res 2006;12:4705–4712.

15. Raber I, Frazer MB, Zenilla JA, Asnani A. Uridine triacetate for severe fluoropyrimidine cardiotoxicity in a patient with thymidylate synthase gene variants. JACC Cardiovasc Therapies 2020;2:329–332.

16. Pareek N, Cevallos J, Moliner P, Shah M, Tan LL, Chambers V et al. Activity and outcomes of a cardio-oncology service in the United Kingdom—a five-year experience. Eur J Heart Fail 2018;20:1721–1731.

17. Kappel C, Rushton M, Johnson C, Aseyev O, Small G, Law A et al. Clinical experience of patients referred to a multidisciplinary cardio-oncology clinic: an observational cohort study. Curr Oncol 2019;26:322–7.

18. Rushton M, Crawley F, Sulpher J, Johnson C, Dent S. Cardiotoxicity in breast cancer patients: a single center, retrospective review. Prenz Pediatr Cardiol 2015;39:67–69.